LC
Louise Chen Scotiabank Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Sarepta Therapeutics
SRPT
$1.93B
| $18.46 | $80 |
333%
upside
| Sector Outperform | 3 months ago |
|
2
Edgewise Therapeutics
EWTX
$1.54B
| $14.62 | $14 |
4%
downside
| Sector Perform | 5 months ago |
|
3
Innoviva
INVA
$1.32B
| $20.92 | $55 |
163%
upside
| Sector Outperform | 6 months ago |
|
4
PTC Therapeutics
PTCT
$4.61B
| $58.01 | $55 |
5%
downside
| Sector Perform | 6 months ago |
|
5
Perspective Therapeutics
CATX
$263M
| $3.54 | $15 |
324%
upside
| Sector Outperform | 6 months ago |
|
|
PVLA
6
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $54.14 | $50 |
8%
downside
| Sector Outperform | 6 months ago |
|
7
Ardelyx
ARDX
$1.58B
| $6.57 | $15 |
128%
upside
| Sector Outperform | 6 months ago |
|
8
Cogent Biosciences
COGT
$1.81B
| $12.94 | $17 |
31%
upside
| Sector Outperform | 6 months ago |
|
9
Avidity Biosciences
RNA
$6.24B
| $48.47 | $70 |
44%
upside
| Sector Outperform | 6 months ago |
|
10
Dyne Therapeutics
DYN
$1.88B
| $13.24 | $50 |
278%
upside
| Sector Outperform | 6 months ago |
|
11
ARS Pharmaceuticals
SPRY
$1.06B
| $10.69 | $30 |
181%
upside
| Sector Outperform | 6 months ago |
|
12
Zai Lab
ZLAB
$3.34B
| $30 | $55 |
83%
upside
| Sector Outperform | 6 months ago |
|
13
Novo Nordisk
NVO
$249B
| $56.14 | $160 |
185%
upside
| Overweight | 10 months ago |
|
14
Pfizer
PFE
$140B
| $24.54 | $45 |
83%
upside
| Overweight | 10 months ago |
|
15
Johnson & Johnson
JNJ
$431B
| $178.76 | $215 |
20%
upside
| Overweight | 10 months ago |
|
16
Merck
MRK
$210B
| $84.05 | $155 |
84%
upside
| Overweight | 11 months ago |
|
17
Eli Lilly
LLY
$666B
| $742.91 | $885 |
19%
upside
| Overweight | 11 months ago |
|
18
AbbVie
ABBV
$376B
| $213 | $200 |
6%
downside
| Overweight | 1 year ago |
|
19
Regeneron Pharmaceuticals
REGN
$60.1B
| $567.22 | $925 |
63%
upside
| Neutral | 1 year ago |
|
20
Rocket Pharmaceuticals
RCKT
$349M
| $3.23 | $65 |
1,912%
upside
| Overweight | 1 year ago |
|
|
IMAB
21
I-MAB
IMAB
$355M
| $4.35 | $25 |
475%
upside
| Overweight | 2 years ago |
|
22
HUTCHMED
HCM
$2.55B
| $14.84 | $50 |
237%
upside
| Overweight | 2 years ago |
|
23
Arcutis Biotherapeutics
ARQT
$1.94B
| $16.21 | $50 |
208%
upside
| Overweight | 2 years ago |
|
24
Factset
FDS
$14B
| $369.48 | $258 |
30%
downside
| Neutral | 5 years ago |
|
25
Teva Pharmaceuticals
TEVA
$21.2B
| $18.48 | $15 |
19%
downside
| Neutral | 5 years ago |
|